Online inquiry

IVTScrip™ pSP6-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector   (CAT#: GTVCR-WQ34MR)

This product GTVCR-WQ34MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the SP6 promoter to efficiently generate mRNA ecoding antibody which targeting CA9. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter SP6
Resistance Ampicillin
Species Chimeric
RefSeq NM_001216.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pSP6-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector (GTVCR-WQ34MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ2397MR IVTScrip™ pSP6-VEE-mRNA-Anti-EGFL7, RG7414 Vector Vector RG7414
GTVCR-WQ2012MR IVTScrip™ pT7-VEE-mRNA-Anti-ERBB2, MM-302 Vector Vector MM-302
GTVCR-WQ1676MR IVTScrip™ pT7-VEE-mRNA-Anti-FGF23, KRN-23 Vector Vector KRN-23
GTVCR-WQ1752MR IVTScrip™ pT7-VEE-mRNA-Anti-SOST, LY2541546 Vector Vector LY2541546
GTVCR-WQ1264MR IVTScrip™ pT7-VEE-mRNA-Anti-CLDN18, GC-182 Vector Vector GC-182
GTVCR-WQ196MR IVTScrip™ pT7-VEE-mRNA-Anti-CD40, ABBV-927 Vector Vector ABBV-927
GTVCR-WQ1118MR IVTScrip™ pSP6-VEE-mRNA-Anti-ITGAV, DI-17E6 Vector Vector DI-17E6
GTVCR-WQ1543MR IVTScrip™ pT7-VEE-mRNA-Anti-MS4A1, IMMU-106 Vector Vector IMMU-106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW